Abstract
The promise of gene therapy has been dimmed in the past few years by a number of setbacks, including the development of T-cell leukemia in infants treated for severe combined immunodeficiency. A recent study suggests that these cases do not augur ill for the field as a whole and that specific changes to gene-therapy protocols may reduce the chances that such therapy will inadvertently trigger cancer.